These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28880015)

  • 21. Durability of Sustained Virologic Response and Improvement of Fibrosis Markers after Daclatasvir and Asunaprevir Treatment in Genotype 1b Hepatitis C Virus-Infected Patients: a Real Life and Multicenter Study.
    Shin SK; Lee JW; Ra H; Kwon OS; Shin JB; Jin YJ; Lee S; Han KJ; Kim YN; Kim TH; Kim YS; Kim JH
    J Korean Med Sci; 2019 Oct; 34(41):e264. PubMed ID: 31650719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile.
    Vargas CL; Espinoza MA; Giglio A; Soza A
    PLoS One; 2015; 10(11):e0141660. PubMed ID: 26544203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.
    Akuta N; Toyota J; Karino Y; Ikeda F; Ido A; Tanaka K; Takaguchi K; Naganuma A; Tomita E; Chayama K; Fujiyama S; Inada Y; Yoshiji H; Watanabe H; Ishikawa H; McPhee F; Noviello S; Kumada H
    J Gastroenterol; 2018 Sep; 53(9):1089-1097. PubMed ID: 29500489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison.
    Swallow E; Kelley C; Signorovitch J; Wygant G; McPhee F
    J Comp Eff Res; 2016 May; 5(3):273-9. PubMed ID: 26793987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between alanine aminotransferase elevation and UGT1A1*6 polymorphisms in daclatasvir and asunaprevir combination therapy for chronic hepatitis C.
    Maekawa S; Sato M; Kuratomi N; Inoue T; Suzuki Y; Tatsumi A; Miura M; Matsuda S; Muraoka M; Nakakuki N; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Sato T; Sakamoto M; Murakawa M; Nakagawa M; Asahina Y; Enomoto N
    J Gastroenterol; 2018 Jun; 53(6):780-786. PubMed ID: 29094205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance-associated substitution test.
    Jang ES; Kim KA; Kim YS; Kim IH; Lee BS; Lee YJ; Chung WJ; Jeong SH
    J Med Virol; 2019 Dec; 91(12):2158-2165. PubMed ID: 31452206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection.
    Toyota J; Karino Y; Suzuki F; Ikeda F; Ido A; Tanaka K; Takaguchi K; Naganuma A; Tomita E; Chayama K; Fujiyama S; Inada Y; Yoshiji H; Watanabe H; Ishikawa H; Hu W; McPhee F; Linaberry M; Yin PD; Swenson ES; Kumada H
    J Gastroenterol; 2017 Mar; 52(3):385-395. PubMed ID: 27502287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study.
    Roulot D; Thibault V; Laforest C; Fontaine H; Bronowicki JP; Asselah T; Bourlière M; Canva V; Leroy V; Loustaud-Ratti V; Ouzan D; Zoulim F; Schischmanoff O; Rousseau C; Renault A; Petrov-Sanchez V; Diallo A; Bellissant E; Serfaty L;
    Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):302-309. PubMed ID: 29271782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
    Manns M; Pol S; Jacobson IM; Marcellin P; Gordon SC; Peng CY; Chang TT; Everson GT; Heo J; Gerken G; Yoffe B; Towner WJ; Bourliere M; Metivier S; Chu CJ; Sievert W; Bronowicki JP; Thabut D; Lee YJ; Kao JH; McPhee F; Kopit J; Mendez P; Linaberry M; Hughes E; Noviello S;
    Lancet; 2014 Nov; 384(9954):1597-605. PubMed ID: 25078304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients.
    Everson GT; Sims KD; Thuluvath PJ; Lawitz E; Hassanein T; Rodriguez-Torres M; Desta T; Hawkins T; Levin JM; Hinestrosa F; Rustgi V; Schwartz H; Younossi Z; Webster L; Gitlin N; Eley T; Huang SP; McPhee F; Grasela DM; Gardiner DF
    Liver Int; 2016 Feb; 36(2):189-97. PubMed ID: 26473667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C genotype 1b.
    Endo D; Satoh K; Shimada N; Hokari A; Aizawa Y
    World J Gastroenterol; 2017 Apr; 23(13):2355-2364. PubMed ID: 28428715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic Hepatitis C Treatment with Daclatasvir Plus Asunaprevir Does Not Lead to a Decreased Quality of Life.
    Kawakubo M; Eguchi Y; Okada M; Iwane S; Oeda S; Otsuka T; Nakashita S; Araki N; Koga A
    Intern Med; 2018 Jul; 57(14):1959-1966. PubMed ID: 29526929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα.
    Serti E; Park H; Keane M; O'Keefe AC; Rivera E; Liang TJ; Ghany M; Rehermann B
    Gut; 2017 Apr; 66(4):724-735. PubMed ID: 26733671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C.
    Zappulo E; Scotto R; Buonomo AR; Maraolo AE; Pinchera B; Gentile I
    Expert Opin Pharmacother; 2020 Feb; 21(3):261-273. PubMed ID: 31914336
    [No Abstract]   [Full Text] [Related]  

  • 35. Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C.
    Kato K; Shimada N; Atsukawa M; Abe H; Itokawa N; Matsumoto Y; Agata R; Tsubota A
    PLoS One; 2019; 14(7):e0219022. PubMed ID: 31291311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Hip joint synovitis associated with daclatasvir plus asunaprevir combination therapy to treat chronic HCV infection in elderly patients: a case report].
    Kimura Y; Inuiguchi F; Ohno K; Hinata M
    Nihon Shokakibyo Gakkai Zasshi; 2018; 115(7):662-669. PubMed ID: 29998989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing.
    Takeda H; Ueda Y; Inuzuka T; Yamashita Y; Osaki Y; Nasu A; Umeda M; Takemura R; Seno H; Sekine A; Marusawa H
    Sci Rep; 2017 Mar; 7():45605. PubMed ID: 28361915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection.
    Signorovitch JE; Betts KA; Song Y; Sorg RA; Li J; Behl AS; Kalsekar A
    J Comp Eff Res; 2015 Nov; 4(6):593-605. PubMed ID: 26159375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The practical management of chronic hepatitis C infection in Japan - dual therapy of daclatasvir + asunaprevir.
    Hayes CN; Imamura M; Chayama K
    Expert Rev Gastroenterol Hepatol; 2017 Feb; 11(2):103-113. PubMed ID: 27936974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
    Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
    Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.